☆ 4.5 Article

Trabectedin for the treatment of breast cancer

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)

Journal

EXPERT OPINION ON INVESTIGATIONAL DRUGS

Volume 25, Issue 1, Pages 105-115

Publisher

TAYLOR & FRANCIS LTD

DOI: 10.1517/13543784.2016.1124086

Keywords

BRCA mutation; DNA repair; metastatic breast cancer; trabectedin

Categories

Pharmacology & Pharmacy

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Introduction: Trabectedin is an anti-tumor compound registered in Europe and in several other countries, for the second-line treatment of soft tissue sarcoma (STS) and for ovarian cancer in combination with liposomal doxorubicin. Trabectedin inhibits cancer cell proliferation mainly affecting the transcription regulation. Trabectedin also acts as a modulator of tumor microenvironment by reducing the number of tumor associated macrophages (TAM). Because of its unique mechanism of action, trabectedin has the potential to act as antineoplastic agent also in several solid malignancies, including breast cancer (BC).Areas covered: This article reviews the preclinical and clinical data of trabectedin focusing on development in metastatic BC (mBC). Comments regarding the nature and the results of these trials are included.Expert opinion: Trabectedin is thought to have a crucial activity with defective DNA-repair machinery and also in modulating the tumor micro-environment and the immune-system of cancer patients. From the current available data, we recognize a potential activity of trabectedin in mBC and support the renewed efforts to better elucidate the value of trabectedin in this indication.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Oncology

Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients-a systematic review and meta-analysis

Tamas Fazekas, Adam D. Szeles, Brigitta Teutsch, Anita Csizmarik, Balint Vekony, Alex Varadi, Tamas Koi, Zsolt Lang, Nandor Acs, Zsolt Kopa, Peter Hegyi, Boris Hadaschik, Viktor Gruenwald, Peter Nyirady, Tibor Szarvas

Summary: This meta-analysis assessed the efficacy of abiraterone, enzalutamide, and docetaxel in BRCA1/2 mutation-positive mCRPC patients. The results showed that enzalutamide may have a better therapeutic effect for these patients, but more studies are needed to provide higher-level evidence.

PROSTATE CANCER AND PROSTATIC DISEASES (2022)

Add to Collection

Article Oncology

Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

Andrea Loehr, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H. Bryce, Ray McDermott, Brieuc Sautois, Nicholas J. Vogelzang, Richard M. Bambury, Eric Voog, Jingsong Zhang, Josep M. Piulats, Arif Hussain, Charles J. Ryan, Axel S. Merseburger, Gedske Daugaard, Axel Heidenreich, Karim Fizazi, Celestia S. Higano, Laurence E. Krieger, Cora N. Sternberg, Simon P. Watkins, Darrin Despain, Andrew D. Simmons, Melanie Dowson, Tony Golsorkhi, Simon Chowdhury, Wassim Abida

Summary: The study showed that plasma, tissue, and local testing of mCRPC patients can effectively identify men with BRCA(+) mCRPC who can benefit from treatment with the PARP inhibitor rucaparib.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers

Jie Sun, Futao Chu, Jiani Pan, Yaxin Zhang, Lu Yao, Jiuan Chen, Li Hu, Juan Zhang, Ye Xu, Xiaojia Wang, Wenming Cao, Yuntao Xie

Summary: The purpose of this study is to develop a risk prediction model for contralateral breast cancer(CBC) in patients with BRCA1/2 variants. The study found that age, family history, variant location, and endocrine therapy are associated with the risk of CBC. The model provides a useful tool for BRCA1/2 carriers to select risk-reducing strategies based on individual CBC risk.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Andrew N. J. Tutt, Judy E. Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmana, Susan M. Domchek, Karen A. Gelmon, Simon J. Hollingsworth, Larissa A. Korde, Barbro Linderholm, Hanna Bandos, E. Senkus, Jennifer M. Suga, Z. Shao, Andrew W. Pippas, Zbigniew Nowecki, Tomasz Huzarski, Patricia A. Ganz, Peter C. Lucas, Nigel Baker, Sibylle Loibl, Robin McConnell, Martine Piccart, Rita Schmutzler, Guenther G. Steger, Joseph P. Costantino, Amal Arahmani, Norman Wolmark, Eleanor McFadden, Vassiliki Karantza, Sunil R. Lakhani, Greg Yothers, Christine Campbell, Charles E. Geyer

Summary: In patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than placebo. Olaparib had limited effects on global patient-reported quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Chemistry, Medicinal

Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA

Cheng Wang, Lailiang Qu, Shang Li, Fucheng Yin, Limei Ji, Wan Peng, Heng Luo, Dehua Lu, Xingchen Liu, Xinye Chen, Lingyi Kong, Xiaobing Wang

Summary: The dual action of PARP inhibitors and EZH2 inhibitors can enhance the treatment of TNBC, with the compound 5a showing potential in reducing sensitivity to inhibitors in BRCA cells.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection

Article Oncology

Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial

Elzbieta Senkus, Suzette Delaloge, Susan M. Domchek, Pierfranco Conte, Seock-Ah Im, Binghe Xu, Anne Armstrong, Norikazu Masuda, Anitra Fielding, Mark Robson, Nadine Tung

Summary: In the primary analysis of the phase III OlympiAD trial, olaparib significantly extended the progression-free survival in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer compared to chemotherapy treatment. Subgroup analyses confirmed the consistent benefit of olaparib across various patient subgroups.

INTERNATIONAL JOURNAL OF CANCER (2023)

Add to Collection

Review Oncology

BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms

Naomie Devico Marciano, Gianna Kroening, Farshid Dayyani, Jason A. Zell, Fa-Chyi Lee, May Cho, Jennifer Goldstein Valerin

Summary: This article discusses the impact of genetic mutations on the development and treatment of pancreatic cancer, particularly focusing on the role of BRCA1 and BRCA2 genes. These mutations affect various aspects of cellular function and may provide new targets for pancreatic cancer treatment. Patients with BRCA mutations show increased sensitivity to certain treatments, but resistance can also occur. Therefore, the development of novel therapies is urgently needed.

CANCERS (2022)

Add to Collection

Review Biochemistry & Molecular Biology

BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations

Sidrah Shah, Rachelle Rachmat, Synthia Enyioma, Aruni Ghose, Antonios Revythis, Stergios Boussios

Summary: Prostate cancer ranks fifth in cancer-related mortality in men worldwide, and DNA damage is implicated in its pathogenesis. Impaired DDR pathways play a role in prostate carcinogenesis, with germline or somatic mutations in DDR genes being found in primary and metastatic prostate cancer.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Medicine, Research & Experimental

Targeting the DNA repair pathway for breast cancer therapy: Beyond the molecular subtypes

Yuting Qu, Sisi Qin, Zhihui Yang, Zhuolin Li, Qinhao Liang, Ting Long, Weiyun Wang, Dan Zeng, Qing Zhao, Zehua Dai, Qing Ni, Fei Zhao, Wootae Kim, Jing Hou

Summary: DNA repair is an essential mechanism in cells for protecting against DNA damage. Dysfunctions in this repair pathway are closely associated with cancer development and progression, but also offer opportunities for targeted therapy. Recent research has focused on developing DNA repair inhibitors, such as PARP1 inhibitors, which have shown promising results in treating breast cancer. This review summarizes the research progress and clinical implementation of targeted treatments for the DNA repair pathway, specifically focusing on BRCA and BRCAness.

BIOMEDICINE & PHARMACOTHERAPY (2023)

Add to Collection

Article Medicine, General & Internal

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype

Heidi Fettke, Chao Dai, Edmond M. Kwan, Tiantian Zheng, Pan Du, Nicole Ng, Patricia Bukczynska, Maria Docanto, Louise Kostos, Siavash Foroughi, Stephen Brown, Lisa-Jane K. Graham, Kate Mahon, Lisa G. Horvath, Shidong Jia, Manish Kohli, Arun A. Azad

Summary: Genomic alterations in DDR genes are common in mCRPC. BRCA genes, especially BRCA2, are key prognostic biomarkers in mCRPC.

EBIOMEDICINE (2023)

Add to Collection

Article Multidisciplinary Sciences

Mutation analysis using cell-free DNA for endocrine therapy in patients with HR plus metastatic breast cancer

Sung Hoon Sim, Han Na Yang, Su Yeon Jeon, Keun Seok Lee, In Hae Park

Summary: ESR1 and PIK3CA mutations in cfDNA were associated with the clinical efficacy of endocrine therapy in HR+ metastatic breast cancer patients. ESR1 mutations were significantly correlated with decreased time to progression of the first endocrine therapy, while PIK3CA mutations were associated with shorter TTP1.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study

Tamar Safra, Barliz Waissengrin, Deanna Gerber, Rinat Bernstein-Molho, Geula Klorin, Lina Salman, Dana Josephy, Rakefet Chen-Shtoyerman, Ilan Bruchim, Melissa K. Frey, Bhavana Pothuri, Franco Muggia

Summary: The study evaluated the incidence of breast cancer and overall survival in ovarian cancer patients carrying BRCA1/2 mutations. It found that routine breast surveillance may be sufficient in ovarian cancer survivors, as the incidence of breast cancer after ovarian cancer was low in BRCA1/2 mutation carriers.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Targeting CK2-mediated phosphorylation of p53R2 sensitizes BRCA-proficient cancer cells to PARP inhibitors

Cong Wang, Ling Tian, Qiang He, Shengbin Lin, Yue Wu, Yiting Qiao, Bo Zhu, Dake Li, Guo Chen

Summary: Depletion of RNR subunit p53R2 impairs HR repair and sensitizes BRCA1/2-WT cancer cells to PARP inhibition, while loss of p53R2 leads to a decrease of HR repair factor CtIP. Casein kinase II (CK2) phosphorylates p53R2 at ser20, activating RNR for dNTPs production. Pharmacologic inhibition of CK2-mediated phosphorylation of p53R2 compromises HR repair capacity, making BRCA1/2-WT cancer cells susceptible to PARP inhibition.

ONCOGENE (2023)

Add to Collection

Article Medicine, General & Internal

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Neeraj Agarwal, Arun A. Azad, Joan Carles, Andre P. Fay, Nobuaki Matsubara, Daniel Heinrich, Cezary Szczylik, Ugo De Giorgi, Jae Young Joung, Peter C. C. Fong, Eric Voog, Robert J. Jones, Neal Shore, Curtis Dunshee, Stefanie Zschaebitz, Jan Oldenburg, Xun Lin, Cynthia G. Healy, Nicola Di Santo, Fabian Zohren, Karim Fizazi

Summary: This study compared the efficacy and safety of talazoparib plus enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer. The results showed that the combination of talazoparib and enzalutamide significantly improved radiographic progression-free survival compared to enzalutamide alone, with clinically meaningful benefits.

LANCET (2023)

Add to Collection

Article Oncology

Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis

Changjun Wang, Yan Lin, Hanjiang Zhu, Yidong Zhou, Feng Mao, Xin Huang, Xingtong Zhou, Xi Cao, Qiang Sun

Summary: This meta-analysis found that breast-conserving therapy (BCT) carries an increased risk of local recurrence but does not significantly impact patient survival in terms of disease-free survival, metastasis-free survival, breast cancer-specific survival, and overall survival.

BREAST CANCER (2022)

Add to Collection

Article Oncology

A comprehensive investigation of histotype-specific microRNA and their variants in Stage I epithelial ovarian cancers

Angelo Velle, Chiara Pesenti, Tommaso Grassi, Luca Beltrame, Paolo Martini, Marta Jaconi, Federico Agostinis, Enrica Calura, Dionyssios Katsaros, Fulvio Borella, Robert Fruscio, Maurizio D'Incalci, Sergio Marchini, Chiara Romualdi

Summary: In this study, we investigated the expression of isomiRs in different histological subtypes of Stage I epithelial ovarian cancer (EOC) for the first time, aiming to gain new insights into their biological role in tumor growth and progression.

INTERNATIONAL JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer

Marco Tagliamento, Alessandra Gennari, Matteo Lambertini, Ramon Salazar, Nadia Harbeck, Lucia Del Mastro, Juan Aguilar-Company, Mark Bower, Rachel Sharkey, Alessia Dalla Pria, Andrea Plaja, Amanda Jackson, Jasmine Handford, Ailsa Sita-Lumsden, Clara Martinez-Vila, Marta Matas, Ana Miguel Rodriguez, Bruno Vincenzi, Giuseppe Tonini, Alexia Bertuzzi, Joan Brunet, Paolo Pedrazzoli, Francesca D'Avanzo, Federica Biello, Alasdair Sinclair, Alvin J. X. Lee, Sabrina Rossi, Gianpiero Rizzo, Oriol Mirallas, Isabel Pimentel, Maria Iglesias, Ana Sanchez de Torre, Annalisa Guida, Rossana Berardi, Alberto Zambelli, Carlo Tondini, Marco Filetti, Francesca Mazzoni, Uma Mukherjee, Nikolaos Diamantis, Alessandro Parisi, Avinash Aujayeb, Aleix Prat, Michela Libertini, Salvatore Grisanti, Maura Rossi, Federica Zoratto, Daniele Generali, Cristina Saura, Gary H. Lyman, Nicole M. Kuderer, David J. Pinato, Alessio Cortellini

Summary: Although breast cancer patients have lower mortality rates from COVID-19, it is important to evaluate the impact of the pandemic in different phases and the effectiveness of vaccination to inform clinical practice.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

N. Colombo, A. Gadducci, J. Sehouli, E. Rulli, J. Maeenpaeae, C. Sessa, A. Montes, N. B. Ottevanger, R. Berger, I. Vergote, M. B. D'Incalci, C. Churruca Galaz, R. Chekerov, G. B. Nyvang, S. Riniker, R. Herbertson, R. Fossati, M. P. Barretina-Ginesta, M. Deryal, M. R. Mirza, E. Biagioli, M. Iglesias, G. Funari, M. Romeo, G. Tasca, B. Pardo, G. Tognon, M. J. Rubio-Perez, A. DeCensi, U. De Giorgi, P. Zola, P. Benedetti Panici, M. Aglietta, V. Arcangeli, C. Zamagni, A. Bologna, A. Westermann, V. Heinzelmann-Schwarz, I. Tsibulak, P. Wimberger, A. Poveda

Summary: This trial aimed to investigate whether treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients with recurrent ovarian cancer (OC). The results showed that TP did not significantly improve OS in patients with a TFIp of 6-12 months, but it remains an effective treatment for patients suffering from persistent platinum toxicities.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments

Carmine Valenza, Dario Trapani, Sara Gandini, Caterina Sposetti, Luca Boscolo Bielo, Antonio Marra, Tommaso Giarratano, Diletta Favero, Laura Cortesi, Luca Moscetti, Mirco Pistelli, Rossana Berardi, Alberto Zambelli, Matteo Lambertini, Lucia Del Mastro, Valentina Guarneri, Claudio Vernieri, Giuseppe Curigliano

Summary: Patients with germinal BRCA pathogenic variant and advanced breast cancer may have enhanced sensitivity to platinum-based chemotherapy and PARP inhibitors. However, the sensitivity and resistance to these treatments may partially overlap. The impact of prior exposure to PARP inhibitors/platinum-based chemotherapy on tumor response to subsequent treatment remains unclear.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Serum thymidine kinase activity in patients with HR- positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial

Luca Malorni, Giampaolo Bianchini, Roberta Caputo, Alberto Zambelli, Fabio Puglisi, Giulia Bianchi, Lucia Del Mastro, Ida Paris, Filippo Montemurro, Giacomo Allegrini, Marco Colleoni, Stefano Tamberi, Claudio Zamagni, Marina E. Cazzaniga, Michele Orditura, Valentina Guarneri, Daniela Castelletti, Matteo Benelli, Mariacristina Di Marino, Grazia Arpino, Michelino De Laurentiis

Summary: In this study, it was found that serum TK1 activity (sTKa) can serve as a novel prognostic and pharmacodynamic biomarker in patients with HR+/HER2- ABC treated with ribociclib plus letrozole as first-line therapy.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Letter Biochemistry & Molecular Biology

Potential pitfalls in the use of real-world data for studying long COVID

Harrison G. Zhang, Jacqueline P. Honerlaw, Monika Maripuri, Malarkodi Jebathilagam Samayamuthu, Brendin R. Beaulieu-Jones, Huma S. Baig, Sehi L'Yi, Yuk-Lam Ho, Michele Morris, Vidul Ayakulangara Panickan, Xuan Wang, Griffin M. Weber, Katherine P. Liao, Shyam Visweswaran, Bryce W. Q. Tan, William Yuan, Nils Gehlenborg, Sumitra Muralidhar, Rachel B. Ramoni, Isaac S. Kohane, Zongqi Xia, Kelly Cho, Tianxi Cai, Gabriel A. Brat, James R. Aaron, Giuseppe Agapito, Adem Albayrak, Giuseppe Albi, Mario Alessiani, Anna Alloni, Danilo F. Amendola, Francois Angoulvant, Li L. L. J. Anthony, Bruce J. Aronow, Fatima Ashraf, Andrew Atz, Paul Avillach, Paula S. Azevedo, James Balshi, Brett K. Beaulieu-Jones, Douglas S. Bell, Antonio Bellasi, Riccardo Bellazzi, Vincent Benoit, Michele Beraghi, Jose Luis Bernal-Sobrino, Melodie Bernaux, Romain Bey, Surbhi Bhatnagar, Alvar Blanco-Martinez, Clara-Lea Bonzel, John Booth, Silvano Bosari, Florence T. Bourgeois, Robert L. Bradford, Gabriel A. Brat, Stephane Breant, Nicholas W. Brown, Raffaele Bruno, William A. Bryant, Mauro Bucalo, Emily Bucholz, Anita Burgun, Tianxi Cai, Mario Cannataro, Aldo Carmona, Charlotte Caucheteux, Julien Champ, Jin Chen, Krista Y. Chen, Luca Chiovato, Lorenzo Chiudinelli, Kelly Cho, James J. Cimino, Tiago K. Colicchio, Sylvie Cormont, Sebastien Cossin, Jean B. Craig, Juan Luis Cruz-Bermudez, Jaime Cruz-Rojo, Arianna Dagliati, Mohamad Daniar, Christel Daniel, Priyam Das, Batsal Devkota, Audrey Dionne, Rui Duan, Julien Dubiel, Scott L. DuVall, Loic Esteve, Hossein Estiri, Shirley Fan, Robert W. Follett, Thomas Ganslandt, Noelia Garcia-Barrio, Lana X. Garmire, Nils Gehlenborg, Emily J. Getzen, Alon Geva, Tobias Gradinger, Alexandre Gramfort, Romain Griffier, Nicolas Griffon, Olivier Grisel, Alba Gutierrez-Sacristan, Larry Han, David A. Hanauer, Christian Haverkamp, Derek Y. Hazard, Bing He, Darren W. Henderson, Martin Hilka, Yuk-Lam Ho, John H. Holmes, Chuan Hong, Kenneth M. Huling, Meghan R. Hutch, Richard W. Issitt, Anne Sophie Jannot, Vianney Jouhet, Ramakanth Kavuluru, Mark S. Keller, Chris J. Kennedy, Daniel A. Key, Katie Kirchoff, Jeffrey G. Klann, Isaac S. Kohane, Ian D. Krantz, Detlef Kraska, Ashok K. Krishnamurthy, Sehi L'Yi, Trang T. Le, Judith Leblanc, Guillaume Lemaitre, Leslie Lenert, Damien Leprovost, Molei Liu, Ne Hooi Will Loh, Qi Long, Sara Lozano-Zahonero, Yuan Luo, Kristine E. Lynch, Sadiqa Mahmood, Sarah E. Maidlow, Adeline Makoudjou, Alberto Malovini, Kenneth D. Mandl, Chengsheng Mao, Anupama Maram, Patricia Martel, Marcelo R. Martins, Jayson S. Marwaha, Aaron J. Masino, Maria Mazzitelli, Arthur Mensch, Marianna Milano, Marcos F. Minicucci, Bertrand Moal, Taha Mohseni Ahooyi, Jason H. Moore, Cinta Moraleda, Jeffrey S. Morris, Michele Morris, Karyn L. Moshal, Sajad Mousavi, Danielle L. Mowery, Douglas A. Murad, Shawn N. Murphy, Thomas P. Naughton, Carlos Tadeu Breda Neto, Antoine Neuraz, Jane Newburger, Kee Yuan Ngiam, Wanjiku F. M. Njoroge, James B. Norman, Jihad Obeid, Marina P. Okoshi, Karen L. Olson, Gilbert S. Omenn, Nina Orlova, Brian D. Ostasiewski, Nathan P. Palmer, Nicolas Paris, Lav P. Patel, Miguel Pedrera-Jimenez, Emily R. Pfaff, Ashley C. Pfaff, Danielle Pillion, Sara Pizzimenti, Hans U. Prokosch, Robson A. Prudente, Andrea Prunotto, Victor Quiros-Gonzalez, Rachel B. Ramoni, Maryna Raskin, Siegbert Rieg, Gustavo Roig-Dominguez, Pablo Rojo, Paula Rubio-Mayo, Paolo Sacchi, Carlos Saez, Elisa Salamanca, Malarkodi Jebathilagam Samayamuthu, L. Nelson Sanchez-Pinto, Arnaud Sandrin, Nandhini Santhanam, Janaina C. C. Santos, Fernando J. Sanz Vidorreta, Maria Savino, Emily R. Schriver, Petra Schubert, Juergen Schuettler, Luigia Scudeller, Neil J. Sebire, Pablo Serrano-Balazote, Patricia Serre, Arnaud Serret-Larmande, Mohsin Shah, Zahra Shakeri Hossein Abad, Domenick Silvio, Piotr Sliz, Jiyeon Son, Charles Sonday, Andrew M. South, Anastasia Spiridou, Zachary H. Strasser, Amelia L. M. Tan, Bryce W. Q. Tan, Byorn W. L. Tan, Suzana E. Tanni, Deanne M. Taylor, Ana I. Terriza-Torres, Valentina Tibollo, Patric Tippmann, Emma M. S. Toh, Carlo Torti, Enrico M. Trecarichi, Yi-Ju Tseng, Andrew K. Vallejos, Gael Varoquaux, Margaret E. Vella, Guillaume Verdy, Jill-Jenn Vie, Shyam Visweswaran, Michele Vitacca, Kavishwar B. Wagholikar, Lemuel R. Waitman, Xuan Wang, Demian Wassermann, Griffin M. Weber, Martin Wolkewitz, Scott Wong, Zongqi Xia, Xin Xiong, Ye Ye, Nadir Yehya, William Yuan, Alberto Zambelli, Harrison G. Zhang, Daniela Zoller, Valentina Zuccaro, Chiara Zucco

NATURE MEDICINE (2023)

Add to Collection

Review Genetics & Heredity

Hereditary Cancer Syndromes: A Comprehensive Review with a Visual Tool

Mattia Garutti, Lorenzo Foffano, Roberta Mazzeo, Anna Michelotti, Lucia Da Ros, Alessandra Viel, Gianmaria Miolo, Alberto Zambelli, Fabio Puglisi

Summary: Hereditary cancer syndromes, though often underdiagnosed, account for nearly 10% of cancers. Identifying pathogenic gene variants could have significant implications for treatment, prevention, and testing, but diagnosing these syndromes can be challenging due to lack of validated criteria and suboptimal performance. Many clinicians are not adequately trained to select patients for genetic testing. This review categorizes hereditary cancer syndromes affecting adults and provides a visual tool to help clinicians in their daily practice.

GENES (2023)

Add to Collection

Review Oncology

Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer

Flavia Jacobs, Elisa Agostinetto, Chiara Miggiano, Rita De Sanctis, Alberto Zambelli, Armando Santoro

Summary: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. Chemotherapy has been the mainstay, but recent studies have shown immune checkpoint inhibitors to be effective as first-line treatment for advanced TNBC expressing PD-L1. However, there are still many open questions regarding the use of immunotherapy in TNBC.

CANCERS (2023)

Add to Collection

Review Oncology

Potential Role of Circulating miRNAs for Breast Cancer Management in the Neoadjuvant Setting: A Road to Pave

Chiara Benvenuti, Paola Tiberio, Mariangela Gaudio, Flavia Jacobs, Giuseppe Saltalamacchia, Sebastiano Pindilli, Alberto Zambelli, Armando Santoro, Rita De Sanctis

Summary: In breast cancer management, neoadjuvant chemotherapy is widely used, but there is a lack of technology that can predict the benefits of neoadjuvant chemotherapy for breast cancer patients. Circulating miRNAs have emerged as potential non-invasive biomarkers for breast cancer and may be useful in diagnosing, predicting, and prognosticating breast cancer patients undergoing neoadjuvant chemotherapy. Among circulating miRNAs, miR-21-5p and miR-34a-5p are the most promising biomarkers for breast cancer patients undergoing neoadjuvant chemotherapy.

CANCERS (2023)

Add to Collection

Article Oncology

Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group

Luca Licata, Deborah Cosentini, Rita De Sanctis, Monica Iorfida, Elena Rota Caremoli, Andrea Vingiani, Edda Lucia Simoncini, Giancarlo Pruneri, Elisabetta Munzone, Giampaolo Bianchini, Alberto Zambelli, Carlo Tondini

Summary: The increasing understanding of breast cancer biology has led to the development of multigene signatures to improve prognostication and risk stratification. The use of these tools in clinical practice has greatly influenced treatment decisions for patients with ER+/HER2- early breast cancer.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Oncology

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fuca, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri

Summary: In 428 patients with HR+/HER2- advanced breast cancer, HER2-low status was found to be independently associated with worse progression-free survival (PFS) and overall survival (OS) compared to HER2-0 status. These findings suggest that HER2-low status could serve as a new prognostic biomarker in this clinical setting.

NPJ BREAST CANCER (2023)

Add to Collection

Article Oncology

A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)

L. Cortesi, M. Venturelli, G. Cortesi, F. Caggia, A. Toss, E. Barbieri, U. De Giorgi, V. Guarneri, A. Musolino, E. De Matteis, A. Zambelli, G. Bisagni, M. Dominici

Summary: In this clinical trial, the efficacy and safety of pembrolizumab plus carboplatin in treating first-line visceral disease BRCA-related luminal breast cancer were investigated. The primary aim of achieving an overall response rate >70% was not met, but further investigation is needed.

ESMO OPEN (2023)

Add to Collection

Review Biochemistry & Molecular Biology

The Role of Female Reproductive Hormones in the Association between Migraine and Breast Cancer: An Unanswered Question

Paola Tiberio, Alessandro Vigano, Mariya Boyanova Ilieva, Sebastiano Pindilli, Anna Bianchi, Alberto Zambelli, Armando Santoro, Rita De Sanctis

Summary: Numerous epidemiological studies have explored the potential link between migraine and breast cancer due to their association with female reproductive hormones. Current evidence suggests a protective role of migraine in breast cancer development, particularly in case-control studies. However, the inconsistency among studies and recent research challenging this concept indicate a more complex relationship between the two conditions. Further studies are needed to validate the protective role of migraine in breast cancer and identify the precise nature of this causal relationship.

BIOMEDICINES (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Clinical Review on the Management of Breast Cancer Visceral Crisis

Chiara Benvenuti, Mariangela Gaudio, Flavia Jacobs, Giuseppe Saltalamacchia, Rita De Sanctis, Rosalba Torrisi, Armando Santoro, Alberto Zambelli

Summary: Visceral crisis is a life-threatening condition in advanced breast cancer, but its clinical definition is unclear, making it challenging to manage. Chemotherapy is recommended as first-line treatment, but its effectiveness is limited and the prognosis is poor. The available evidence is mainly from retrospective studies, and the role of chemotherapy is questioned with the introduction of innovative drugs. This article aims to critically discuss the management of visceral crisis and explore future treatment perspectives.

BIOMEDICINES (2023)

Add to Collection

Review Oncology

Unlocking the Potential of Circulating miRNAs in the Breast Cancer Neoadjuvant Setting: A Systematic Review and Meta-Analysis

Paola Tiberio, Mariangela Gaudio, Silvia Belloni, Sebastiano Pindilli, Chiara Benvenuti, Flavia Jacobs, Giuseppe Saltalamacchia, Alberto Zambelli, Armando Santoro, Rita De Sanctis

Summary: In recent decades, neoadjuvant chemotherapy has been proven to reduce tumor size and improve surgical outcomes in high-risk early or locally advanced breast cancer. However, individual responses to therapy and long-term prognosis remain unpredictable. Circulating microRNAs have emerged as potential non-invasive biomarkers for breast cancer management, but discrepancies between studies hinder their implementation in clinical practice.

CANCERS (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.